Chongqing Fuchuang Pharmaceuticals Research Co., Ltd.

Main study objectives: To evaluate the effects of itraconazole capsules and rifampicin capsules on the main pharmacokinetic parameters of succinate succinate succinate succinate capsules in healthy Chinese subjects; Secondary study objectives: 1) To evaluate the effects of itraconazole capsules and rifampicin capsules on other pharmacokinetic parameters of succinate succinate succinate capsules in healthy Chinese subjects; 2) To evaluate the safety of single-dose oral administration of succinate succinate succinate capsules and combined administration with itraconazole capsules and rifampicin capsules in healthy Chinese subjects; Exploratory objectives: To qualitatively analyze the metabolites in feces of healthy Chinese subjects after single-dose oral administration of succinate succinate succinate capsules and combined administration with itraconazole capsules and rifampicin capsules.

Primary objectives: To evaluate the safety and tolerability of FCN-338 combined with AZA or chemotherapy (cytarabine, daunorubicin) in patients with myeloid neoplasms. To explore the efficacy of FCN-338 combination therapy in patients with myeloid neoplasms. Secondary objectives: 1) To evaluate the pharmacokinetic characteristics of FCN-338 combination therapy in patients with myeloid neoplasms. 2) To evaluate the transfusion independence rate of FCN-338 combination therapy in patients with myeloid neoplasms. 3) To evaluate the hematological improvement (HI) of FCN-338 combination therapy in patients with MDS/CMML.

Primary Objectives: To evaluate the efficacy of FCN-159 versus placebo in the treatment of adult patients with symptomatic, inoperable NF1-related plexiform neurofibromas based on the objective response rate (ORR) assessed by a blinded independent review committee (BIRC). Secondary Objectives: To evaluate the improvement of other radiographic efficacy measures, pain, and cosmetic appearance of FCN-159 versus placebo in the treatment of adult patients with symptomatic, inoperable NF1-related plexiform neurofibromas. To further evaluate the safety of FCN-159 in the treatment of adult patients with symptomatic, inoperable NF1-related plexiform neurofibromas. Exploratory Objectives: To further evaluate the pharmacokinetic (PK) characteristics of oral FCN-159 in adult patients with NF1. To evaluate the improvement of quality of life of adult patients with symptomatic, inoperable NF1-related plexiform neurofibromas with FCN-159. To further evaluate the long-term safety of FCN-159 in the treatment of adult patients with symptomatic, inoperable NF1-related plexiform neurofibromas using patient-reported scales.